Is Lymphopenia Different Between SARS and COVID-19 Patients?

Overview

Journal FASEB J

Specialties Biology
Physiology

Date 2021 Jan 26

PMID 33495994

Citations 14

Authors

Shaomin Yan

Guang Wu

Affiliations

Soon will be listed here.

Abstract

Lymphopenia is commonly observed in SARS and COVID-19 patients although the lymphocyte count is not always below 0.8 × 10 /L in all the patients. It is suggested that lymphopenia serves as a useful predictor for prognosis in the patients. It is also hypothesized that lymphopenia is related to glucocorticoids and apoptosis. However, the ordering between lymphopenia and apoptosis appears different between SARS and COVID-19 patients, ie, lymphopenia is prior to apoptosis in SARS patients whereas apoptosis is prior to lymphopenia in COVID-19 patients. This paper attempts to figure out this contradiction through three players, lymphopenia, glucocorticoids, and apoptosis. Although the literature does not provide a solid explanation, the level of glucocorticoids could determine the ordering between lymphopenia and apoptosis because the administration of high doses of glucocorticoids could lead to lymphopenia whereas low doses of glucocorticoids could benefit patients. In the meantime, this paper raises several questions, which need to be answered in order to better understand the whole course of COVID-19.

Citing Articles

Prolonged lymphopenia and prognoses among inpatients with different respiratory virus infections: A retrospective cohort study.

Fan G, Yang W, Wang D, Xu F, Wang Y, Si C Heliyon. 2024; 10(11):e31733.

PMID: 38867947 PMC: 11167307. DOI: 10.1016/j.heliyon.2024.e31733.

CD4 T-Cell Depression is Linked to the Severity of COVID-19 and Predicts Mortality.

Eryilmaz-Eren E, Koker M, Ulu-Kilic A, Hurmet-Oz H, Ay-Altintop Y, Saatci E Infect Dis Clin Microbiol. 2024; 5(1):23-30.

PMID: 38633909 PMC: 10985810. DOI: 10.36519/idcm.2023.190.

Enhancing voriconazole therapy in liver dysfunction: exploring administration schemes and predictive factors for trough concentration and efficacy.

Zhao Y, Liu H, Xiao C, Hou J, Zhang B, Li J Front Pharmacol. 2024; 14:1323755.

PMID: 38239188 PMC: 10794455. DOI: 10.3389/fphar.2023.1323755.

Gender Differences Associated with Hyper-Inflammatory Conditions in COVID-19 Patients.

Shoeb F, Mahdi F, Hussain I Aging Dis. 2023; 14(2):299-308.

PMID: 37008057 PMC: 10017144. DOI: 10.14336/AD.2022.0830.

Comparing serum ferritin levels during COVID-19 infection and recovery period in pediatric patients with transfusion-dependent thalassemia, a single-center study.

Marhaeni W, Felicia F, Sumadi Jap A, Hartoyo E, Andayani P Front Med (Lausanne). 2023; 10:1056599.

PMID: 36844235 PMC: 9947356. DOI: 10.3389/fmed.2023.1056599.

References

Barnes P . Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011; 163(1):29-43. PMC: 3085866. DOI: 10.1111/j.1476-5381.2010.01199.x. View

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

Fauci A, Dale D, Balow J . Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976; 84(3):304-15. DOI: 10.7326/0003-4819-84-3-304. View

Zheng F, Tang W, Li H, Huang Y, Xie Y, Zhou Z . Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020; 24(6):3404-3410. DOI: 10.26355/eurrev_202003_20711. View

Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F . Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010; 84(24):12658-64. PMC: 3004351. DOI: 10.1128/JVI.01542-10. View

Yan S, Wu G . Is lymphopenia different between SARS and COVID-19 patients?. FASEB J. 2021; 35(2):e21245. PMC: 7995142. DOI: 10.1096/fj.202002512. View

Huang I, Bosch B, Li F, Li W, Lee K, Ghiran S . SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem. 2005; 281(6):3198-203. PMC: 8010168. DOI: 10.1074/jbc.M508381200. View

Thompson B . Glucocorticoids and acute lung injury. Crit Care Med. 2003; 31(4 Suppl):S253-7. DOI: 10.1097/01.CCM.0000057900.19201.55. View

Yang Z, Huang Y, Ganesh L, Leung K, Kong W, Schwartz O . pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004; 78(11):5642-50. PMC: 415834. DOI: 10.1128/JVI.78.11.5642-5650.2004. View

10.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

11.

Channappanavar R, Zhao J, Perlman S . T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014; 59(1-3):118-28. PMC: 4125530. DOI: 10.1007/s12026-014-8534-z. View

12.

Ma-Lauer Y, Carbajo-Lozoya J, Hein M, Muller M, Deng W, Lei J . p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci U S A. 2016; 113(35):E5192-201. PMC: 5024628. DOI: 10.1073/pnas.1603435113. View

13.

Henry B . COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020; 8(4):e24. PMC: 7118650. DOI: 10.1016/S2213-2600(20)30119-3. View

14.

Tang P, Mura M, Seth R, Liu M . Acute lung injury and cell death: how many ways can cells die?. Am J Physiol Lung Cell Mol Physiol. 2008; 294(4):L632-41. DOI: 10.1152/ajplung.00262.2007. View

15.

Nelemans T, Kikkert M . Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections. Viruses. 2019; 11(10). PMC: 6832425. DOI: 10.3390/v11100961. View

16.

Ho J, Ooi G, Mok T, Chan J, Hung I, Lam B . High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003; 168(12):1449-56. DOI: 10.1164/rccm.200306-766OC. View

17.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

18.

Wu X, Shang B, Yang R, Yu H, Ma Z, Shen X . The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells. Cell Res. 2004; 14(5):400-6. PMC: 7091875. DOI: 10.1038/sj.cr.7290240. View

19.

Fehr A, Channappanavar R, Perlman S . Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. Annu Rev Med. 2016; 68:387-399. PMC: 5353356. DOI: 10.1146/annurev-med-051215-031152. View

20.

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View